Reports Q2 revenue $1.112M vs $3.674M last year. “APX3330 has potential to be the first non-invasive, early treatment to delay vision-threatening complications in millions of patients with non-proliferative diabetic retinopathy who otherwise remain untreated, and we are pleased with the progress on our preparations for the next clinical study. We continue to work collaboratively with the U.S. Food and Drug Administration on our submitted Special Protocol Assessment for Phase 2/3 and the overall clinical development plan for APX3330,” said George Magrath, M.D., M.B.A., M.S., CEO of Ocuphire.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUP:
- Ocuphire Pharma to Present at Two Investor Conferences in August
- OCUP Earnings this Week: How Will it Perform?
- Ocuphire Pharma price target lowered to $11 from $18 at JonesResearch
- Ocuphire Pharma to highlight APX3330 at ARVO SIG panel, ASRS meeting
- Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July